Skip to content
HowShorted

Twist Bioscience Corp short interest in 2024

In 2024, Twist Bioscience Corp's disclosed short interest ran from 21.88% of shares outstanding on 12 Jan 2024 to 14.65% on 31 Dec 2024, a change of -7.23 percentage points. The year's high was 21.88% on 12 Jan 2024 and its low 14.65% on 31 Dec 2024, averaging 17.85% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.15 days on 28 Mar 2024. Full history: Twist Bioscience Corp.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Twist Bioscience Corp in 2024

2024 in figures

Start of year
21.88% (12 Jan 2024)
End of year
14.65% (31 Dec 2024)
Change
-7.23 pp
High
21.88% (12 Jan 2024)
Low
14.65% (31 Dec 2024)
Average
17.85%
Highest days to cover
19.15 (28 Mar 2024)
SEC filings marked
8

Every report in 2024

Twist Bioscience Corp short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202421.88%11.32
31 Jan 202421.32%13.23
15 Feb 202421.38%9.3410-Q filed, results (8-K)
29 Feb 202421.44%15.67
15 Mar 202420.78%15.30
28 Mar 202421.20%19.15
15 Apr 202421.19%16.39
30 Apr 202420.49%12.51
15 May 202418.38%6.6110-Q filed, results (8-K)
31 May 202419.05%13.25
14 Jun 202418.63%8.12
28 Jun 202416.44%7.07
15 Jul 202416.37%12.68
31 Jul 202416.84%10.16
15 Aug 202415.72%7.3310-Q filed, results (8-K)
30 Aug 202416.02%14.79
13 Sep 202415.26%9.56
30 Sep 202414.85%13.07
15 Oct 202415.07%15.31
31 Oct 202415.40%16.96
15 Nov 202414.74%9.16
29 Nov 202416.25%10.0710-K filed, results (8-K)
13 Dec 202415.08%11.86
31 Dec 202414.65%10.70

See also: Twist Bioscience Corp's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.